# A Study of CSTI-500 in Patients With Prader-Willi Syndrome

> **NCT07348601** · PHASE2 · RECRUITING · sponsor: **ConSynance Therapeutics** · enrollment: 12 (estimated)

## Conditions studied

- Prader-Willi Syndrome

## Interventions

- **DRUG:** CSTI-500

## Key facts

- **NCT ID:** NCT07348601
- **Lead sponsor:** ConSynance Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07348601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07348601, "A Study of CSTI-500 in Patients With Prader-Willi Syndrome". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT07348601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*